This application describes the creation of the University of Rochester (UR) Clinical Trials Unit (CTU). The UR CTU will consist of an Administrative Component and four Clinical Research Sites (CRSs). The UR CTU is proposing to affiliate with the HIV Vaccine Trials Network (HVTN) and the AIDS Clinical Trials Group (ACTG). Letters of commitment from Dr. Larry Corey, Principal Investigator of the HVTN, and Dr. Constance Benson, Principal Investigator of the ACTG, are included in the Section """"""""Consultants and Letters of Support"""""""". Of the four UR CTU CRSs, one will conduct studies for the HVTN and three will conduct studies for the ACTG. All four CRSs are currently main units or subunits of an existing HIV Vaccine Trials Unit (HVTU) or AIDS Clinical Trials Unit (ACTU). Two CRSs will be located at the UR Medical Center (URMC). One, the UR HVTN CRS, will conduct HVTN studies, and the other, the UR ACTG CRS will conduct ACTG studies. The third CRS will be located at AIDS Community Health Center (ACHC), in Rochester, New York and will perform ACTG studies. The fourth will be located at the State University of New York at Buffalo, the UB CRS, and will perform ACTG studies. The Administrative Core of the UR CTU will be located within the UR Infectious Diseases Division (IDD), which also contains the UR HVTN CRS and the UR ACTG CRS. The UR IDD has a long history of performing NIAID-supported clinical investigation and has been part of the HVTN and ACTG since both programs originated. As a consequence of this history, the IDD has developed approaches to sharing resources, which will be expanded in the proposed CTU. Centralized Clinical Research Functions will include a Processing Laboratory, a Flow Cytometry Laboratory, a Data and Quality Management Team, a Community Education and Outreach Program (CEOP), and an approach to Staff Training. These Functions will be shared by all four CRSs. The CTU will support the research agendas proposed in the HVTN and ACTG Leadership Applications by enrolling subjects in critical studies, focusing on areas in which UR CTU investigators have particular expertise and a demonstrated record of performance. UR CTU investigators will also make important scientific and administrative contributions to the HVTN and ACTG. The UR CTU will serve as a mentoring unit for a CTU based at the Federal University of Sao Paulo in Sao Paulo, Brazil. The research outlined in this proposal is designed to make contributions to the prevention and treatment of HIV infection and AIDS. The proposed UR CTU will affiliate with two large, multicentered programs, the HVTN and the ACTG. The goal of the HVTN is to develop a vaccine that will prevent HIV infection or delay the onset of symptomatic disease. The goal of the ACTG is to develop more effective treatments for established HIV infection in a variety of patient populations. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069511-07
Application #
8402568
Study Section
Special Emphasis Panel (ZAI1-KS-A (M3))
Program Officer
Pouliot, Eileen M
Project Start
2007-02-01
Project End
2013-11-30
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
7
Fiscal Year
2013
Total Cost
$1,597,142
Indirect Cost
$687,376
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Benson, Constance A; Andersen, Janet W; Macatangay, Bernard J C et al. (2018) Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clin Infect Dis 67:1712-1719
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Riddler, Sharon A; Zheng, Lu; Durand, Christine M et al. (2018) Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. Open Forum Infect Dis 5:ofy242
Elizaga, Marnie L; Li, Shuying S; Kochar, Nidhi K et al. (2018) Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial. PLoS One 13:e0202753
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Ocque, Andrew J; Hagler, Colleen E; Morse, Gene D et al. (2018) Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid. J Pharm Biomed Anal 156:163-169
Li, Shuying S; Kochar, Nidhi K; Elizaga, Marnie et al. (2017) DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA. Clin Vaccine Immunol 24:

Showing the most recent 10 out of 110 publications